Compugen (CGEN)
(Delayed Data from NSDQ)
$1.75 USD
+0.03 (1.74%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.74 -0.01 (-0.57%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CGEN 1.75 +0.03(1.74%)
Will CGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEN
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
uniQure (QURE) Soars on New Huntington's Disease Study Data
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Other News for CGEN
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen Earns Milestone from AstraZeneca Trial
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to receive $5M milestone payment from AstraZeneca
Biotech Alert: Searches spiking for these stocks today